Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 7.3. It has been cited 1,324 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.1
From this paper's citation signal
Citation Network Contribution
6.2
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
FWCI
153.38
Citation Percentile
1.0%
Influential Citations
101
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals